An Open Letter from Maria Maccecchini, Ph.D., CEO of Annovis Bio

Dear Shareholders, Employees, Patients, and Their Loved Ones,

As many of you know, our mission at Annovis is deeply rooted in the commitment to restore brain health and improve the quality of life for those who have been affected by neurodegenerative diseases. For me, this journey is not merely professional—it is deeply personal. I have seen the ravages of these diseases firsthand, watching my mom struggle with Alzheimer’s disease as she faded away. While I had dedicated most of my life to protecting nerve cells from dying, my mother's fate intensified my determination to find a solution to this problem.

At Annovis, our passion drives us to constantly explore and expand the potential of our lead candidate, buntanetap. With its unique mechanism of action—targeting multiple toxic proteins simultaneously—we see a future where this drug can make a difference not only in one disease but across a spectrum of neurodegenerative conditions. We also believe in its potential to work in harmony with other treatments, amplifying its impact and offering new possibilities for patients.

Today, I am proud to share a milestone that reflects our dedication and perseverance. We have built a very extensive patent portfolio, securing long-term protection of buntanetap in terms of composition of matter, manufacturing, application, and novel combinations with other drugs that may further improve its function.  These patents are not just legal protections; they are the keys to our future, ensuring that we can continue to push the boundaries of what is possible in the fight against neurodegeneration.

Our portfolio

Let me guide you through our current patent portfolio. Our first three patent families stand as pillars of our work, covering the use of buntanetap for both acute and chronic conditions, along with its groundbreaking mechanism of action. I’m proud to share that almost all claims from these families have been granted in jurisdictions around the world.

We have recently embarked on a new chapter, filing a composition of matter patent and transferring all our claims related to chronic and acute indications, as well as the mechanism of action, to a new crystal form of buntanetap. This strategic move not only strengthens our intellectual property but also extends the expiration date of these patent families to 2044, fortifying our position for the new form.

Since buntanetap continues to show impressive performance for our primary indications – Alzheimer’s and Parkinson’s – by working as a translational inhibitor of neurotoxic proteins, we decided to explore if it can be complemented by existing medications to enhance its efficacy even further. That is why, we have added new patent families for combinations with various drugs used in other diseases, with the most recent addition being the combination with GLP-1 agonists and PDE5 inhibitors. These newly filed patents for combinations are also in the process of being converted to the crystal form of buntanetap.

As we move forward, we will sustain two comprehensive patent portfolios: one preserving the legacy of the original buntanetap (pink) and the other dedicated to the composition of matter for its new form (blue).

Special shout-out

While many have played a role in our patent expansion, I want to shine a particular light on our VP of Process Chemistry, Mike Christie. Mike’s brilliance and dedication were crucial in developing the crystal form of buntanetap. As a co-inventor of the patents related to the new composition of matter and the manufacturing process, Mike's contributions have been instrumental in transferring our claims to this novel composition. His top-tier expertise has been the bedrock of these achievements, and without it, we wouldn't have reached this milestone.

Finally, I would like to express gratitude to shareholders, KOLs and patients for their continued support and trust in our mission. Together, we are making truly meaningful progress in treating neurodegenerative diseases, building block by block a brighter future for millions of people worldwide.

"The best way to predict the future is to invent it."

— Alan Kay

Best regards,

Maria Maccecchini, Ph.D.
Founder, President and CEO of Annovis Bio

‍